Armistice Capital, LLC Reports New 4.99% Stake in GlucoTrack, Inc. (GCTK)

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A with the SEC, reporting a 4.99% ownership stake in GlucoTrack, Inc. (GCTK). The reporting persons collectively hold 102,115 shares of common stock, representing a significant increase from their previously reported zero position. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. Armistice Capital, LLC, acting as an investment adviser, and Steven Boyd, as its managing member, share voting and dispositive power over the reported securities. The shares are held on behalf of the Armistice Capital Master Fund Ltd., a Cayman Islands exempted company. This amendment follows an event date of March 31, 2026, and confirms that the reporting persons now hold less than 5% of the company's outstanding common stock.